Search the Newsreel

Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary

Invivyd, Inc. reported its second-quarter 2026 results, showing a 21.2% year-over-year revenue increase to $14.29 million, driven by demand for PEMGARDA. Despite this, the company experienced a widened net loss of $(44.39) million, resulting in a diluted loss per share of $(0.14). Significant progress …

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Invivyd, Inc. announced its Q2 2026 financial results, reporting $14.3 million in PEMGARDA net product revenue, a 21% increase year-over-year. The company completed enrollment for its VYD2311 DECLARATION pivotal clinical trial and LIBERTY clinical trial, with top-line data for both anticipated in late Q3 …

IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%

Invivyd Inc (IVVD) Stock News Today

This article provides real-time stock information for Invivyd Inc (IVVD), including its current trading price, market cap, and recent performance. It also indicates that more news and analysis regarding the company will be available soon. The page serves as a hub for investors to …

Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Invivyd (IVVD) to Release Earnings on Thursday

Invivyd (IVVD) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $0.15 per share and revenue of $14.4 million. The company's previous quarter missed expectations, and investor sentiment remains mixed, with a …

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $8.00. Institutional investors and hedge funds hold a significant 70.36% stake in the company, with some major firms increasing their positions. Despite this, Invivyd's shares opened …

Invivyd (IVVD) awards 1,125,000 stock options to CMO and Chief Epidemiologist

Invivyd, Inc. granted its Chief Medical Officer and Chief Epidemiologist, Michael Mina, 1,125,000 stock options with an exercise price of $0.535 per share, expiring on July 30, 2036. The options vest over four years, with 25% vesting on July 31, 2027, and the remainder …

Invivyd grants 277,500 inducement stock options to new hires at $0.54 exercise price

Invivyd has granted 277,500 inducement stock options to 10 new non-executive employees under its 2026 Inducement Plan. The options have an exercise price of $0.54 per share, vesting over four years, with a 10-year term. This news brief was generated by Public Technologies (PUBT) …

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd, Inc. announced that it granted stock options to ten newly hired non-executive employees to purchase an aggregate of 277,500 shares of its common stock. These grants serve as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4) and the …

Invivyd Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against Invivyd, Inc. (NASDAQ: IVVD) and reminds investors of an April 3, 2023 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Invivyd made false and misleading statements …

Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Invivyd Inc (IVVD), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The stock is currently ranked 10th in the Pharmaceuticals industry for price momentum and is trading …

Invivyd Inc (IVVD) Institutional Confidence

Invivyd Inc (IVVD) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 96.20%, marking a significant quarter-over-quarter increase of 28.05%. Janus Henderson Investors is listed as a major institutional shareholder with a 28.21% increase …

Invivyd, Inc. Revenue Breakdown – NASDAQ:IVVD

Invivyd, Inc. (NASDAQ:IVVD) generated $53.43 million USD in revenue last year, primarily from its Antibody-based Solutions segment. This marks a significant increase from the $25.38 million USD recorded in the previous year. The United States was the company's largest contributor to revenue.

Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Invivyd Inc (IVVD), noting its current valuation score is 6.90, ranking 139 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -1.96, which is significantly below its recent high and above its …

BlackRock (NYSE: BLK) discloses 5.5% beneficial stake in Invivyd (IVVD)

BlackRock, Inc. has disclosed a passive beneficial ownership stake of 5.5% in Invivyd, Inc. common stock, as reported in a Schedule 13G SEC filing. This represents 16,124,696 shares, with BlackRock exercising sole voting power over 15,974,045 shares and sole dispositive power over all beneficially …

Invivyd Inc (IVVD) Cash Flow

This article provides a detailed historical cash flow statement for Invivyd Inc (IVVD), including operating, investing, and financing cash flows presented quarterly and annually. It details changes in various cash flow components and offers FAQs defining key financial terms like operating cash flow, investing …

Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Invivyd Inc (IVVD), listing its major shareholders and their proportions, as well as an analysis of shareholder types such as hedge funds, investment advisors, and venture capital firms. It also provides a historical overview of institutional shareholding, …

Invivyd Inc IVVD Income Statement

This article provides a detailed quarterly and annual income statement for Invivyd Inc. (IVVD), including revenue, operating expenses, profit, and earnings per share. It also includes an FAQ section explaining how to interpret the income statement and key financial metrics. The data shows recent …

Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Invivyd Inc.'s (IVVD) historical dividend payouts and stock splits. It indicates that the company has distributed a total of $0.00 USD in dividends over the past five years, with no specific dividend data available. The content also briefly …

IVVD|Invivyd Inc|Price:0.611|Chg%:+0.002

Invivyd Inc (IVVD) has a strong financial health and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. Institutional ownership is notably high, and analysts have issued "Buy" ratings with a potential upside of over 1500%. Despite recent weak stock …

Invivyd Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Invivyd received a Nasdaq deficiency letter because its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of …

IVVD stock trades around recent lows as Invivyd highlights COVID-19 antibody pipeline

Invivyd Inc. (IVVD) stock is trading near recent lows as the company focuses on its monoclonal antibody pipeline for evolving COVID-19 variants, despite significant accumulated operating losses and minimal revenue. The company maintains sufficient cash reserves for several quarters, but future financing or partnerships …

Invivyd stock trades around recent lows as investors weigh antibody revenue outlook

Invivyd's stock is trading near recent lows as investors analyze the company's antibody revenue outlook. The company reported full-year 2024 revenue of $203.6 million, primarily from its COVID-19 antibody adintrevimab, but anticipates a decline in sales in 2025 as pandemic demand normalizes. Invivyd is …